Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemotherapy vs placebo plus chemotherapy in first-line PD-L1–positive ESCC
CTR20190911Phase 3Completed
- Sponsor
- Henlius
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henlius. Started May 2019; status: completed.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20190911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190911.